Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions | Zendy

Gian Paolo Fadini | Zendy; Mayur Sarangdhar | Zendy; Angelo Avogaro | Zendy

Open Access

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions

Author(s) -

Gian Paolo Fadini,

Mayur Sarangdhar,

Angelo Avogaro

Publication year - 2018

Publication title -

diabetes therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.907

H-Index - 33

ISSN - 1869-6961

DOI - 10.1007/s13300-018-0408-2

Subject(s) - saxagliptin , medicine , pharmacovigilance , adverse event reporting system , alogliptin , concomitant , dipeptidyl peptidase 4 inhibitor , adverse effect , metformin , pharmacology , heart failure , drug , diabetes mellitus , type 2 diabetes , insulin , endocrinology , sitagliptin

In the SAVOR-TIMI trial, the risk of heart failure (HF) was increased by 27% in T2D patients randomized to the dipeptidyl peptidase-4 inhibitor (DPP4i) saxagliptin. Other studies have provided inconsistent results regarding this association. Herein, we performed a pharmacovigilance analysis of the rate of HF associated with DPP4is, focusing on stimulated reporting and moderation by drug-drug interactions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research